Earticle

현재 위치 Home

원보

의약품 해외 수출을 위한 한국 제약산업의 해결과제
Barriers Impeding Domestic Pharmaceutical Industry’s Exportation to Developed Countries

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 KCI 등재 바로가기
  • 통권
    제23권 제2호 (2013.06)바로가기
  • 페이지
    pp.106-113
  • 저자
    윤수진, 민지혜, 조은
  • 언어
    한국어(KOR)
  • URL
    https://www.earticle.net/Article/A200951

※ 기관로그인 시 무료 이용이 가능합니다.

4,000원

원문정보

초록

영어
Background: For Korean pharmaceutical industry to continue to grow, it is requisite to enter the global markets of developed countries. However, the export volume has fallen short of 10% of the gross sales and the industry has only recently warming up to prepare the globalization along with suchlike the Columbus Project. Purpose: This research was conducted to identify the difficulties Korean pharmaceutical companies perceived and to discover the gap in the needs for the government aid the companies have been seeking in the purpose of entering the developed pharmaceutical markets. Method: A survey method was used for this research. Six experts were surveyed and provided comments for the pre-questionnaire. Then, a final questionnaire was developed consisting of 10 items on regulatory-related and another 10 items on non-regulatory-related factors in drug exportation using the Likert scale (1 to 5). The survey sample was 30 Korean companies which have participated in the Columbus Project since 2010. Results: Nineteen (63%) companies responded to the survey. Most companies perceived difficulty (mean = 4.19) over the entire pathway of the regulatory process of global markets. Clinical trials and post-marketing surveillance were remarked as the most difficult barrier to follow the regulatory globalization. Among non-regulatory related factors, marketing, arranging a distribution network, obtaining experts, and projecting a timeline in exportation were brought up as the most difficulty. Conclusion: Especially, cost and language barrier were considered as the main cause producing these difficulties across regulatory and non-regulatory processes and accordingly, securing both long term budget and experts at governmental level was suggested by the domestic pharmaceutical companies.

목차

Abstract
 연구 배경
 연구 방법
  설문지 개발 과정
  연구 대상
  연구 분석
 연구 결과
  선진시장 수출 시 한국기업이 봉착하는 인허가 관련 해결과제와 극복방안
  인허가 절차 외의 요인 중에서 한국 기업의 당면 과제와 지원방안
  구체적 해결과제와 지원방안의 그룹핑 결과
 고찰
 결론
 감사의 말씀
 참고문헌

키워드

Domestic pharmaceutical industry global market exportation drug regulation

저자

  • 윤수진 [ Sujin Yun | 성균관대학교 임상약학대학원 보건사회약학과 ]
  • 민지혜 [ Jihye Min | 한림대학교 강남성심병원 ]
  • 조은 [ Eun Cho | 숙명여자대학교 약학대학 ] Correspondence to

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제23권 제2호

    피인용수 : 0(자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      페이지 저장